US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.18 against a street estimate of 0.17 — a beat of 5.9%.
Analysts rate Stevanato Group SpA a buy (9 buy, 4 hold, 0 sell out of 13) with an average price target of $22.54.
CONFIDENT STVN delivered Q2 revenue growth of 8% YoY to €302M with 26% adjusted EBITDA margin. High-value solutions grew 16%, driven by biologics. Alina device gained European approval; divestiture of non-core Balda C. Brewer completed. Full-year guidance raised modestly on currency tailwinds and organic growth. Q2 FY26 Alina approvals in multiple European countries; North American approvals expected H2 2026. Fishers (US) and Latina (Italy) expansion on track. Analysts pushed on segment growth attribution (GLP vs. non-GLP biologics), Alina upside, and Engineering stabilization. Management emphasized biologics as durable tailwind beyond single GLP class and highlighted approvals as catalyst for biosimilar validation. Engineering margins improved 370 bps despite revenue decline; optimization plan credited. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| Conestoga Capital Advisors, LLC | 2.57% |
| Neuberger Berman Group LLC | 2.06% |
| TimesSquare Capital Management, LLC | 1.27% |
| Van Berkom and Associates Inc | 1.09% |
| Artisan Partners Limited Partnership | 0.95% |
| BAMCO Inc | 0.91% |
| Morgan Stanley - Brokerage Accounts | 0.48% |
| Crédit Agricole S.A. | 0.48% |
| Document | Date |
|---|---|
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Q3 2026 revenue was EUR 326,063 thousand, up from EUR 303,167 thousand in Q3 2025. • Q3 2026 net profit was EUR 41,838 thousand, | 2026-11-03 |
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Q3 2026 revenue increased 8% year over year to €326M, from €303M. • Adjusted EBITDA increased 14% to €88.8M; adjusted EBITDA marg | 2026-11-03 |
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue increased 8% to €326.1 million; organic revenue also increased 8%. • Adjusted EBITDA increased 14% to | 2026-11-03 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 revenue rose 8% year over year to €302 million, unchanged at constant currency. • Adjusted EBITDA increased 21% to €78.7 m | 2026-08-06 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Revenue increased 7.3% year over year to EUR 302,003 thousand in Q2 2026, from EUR 280,037 thousand; first-half revenue rose 7.3% | 2026-08-04 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 revenue rose 8% year over year to €302M, driven by 9% growth in the Biopharmaceutical and Diagnostic Solutions (BDS) segme | 2026-08-04 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 revenue increased 8% year over year to €302.0 million. • High-value solutions revenue increased 16% to €135.9 million, re | 2026-08-04 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • The document is a Form 6-K filing by Stevanato Group S.p.A., dated June 5, 2026. • It incorporates a press release dated June 3, | 2026-06-05 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.06 / share ex-date Jun 11, 2026 · pay Jul 29, 2026 | 2026-06-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Stevanato Group SpA — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.